Anthony P Conley, MD

Alıntı yapanlar

	Hepsi	2019 yılından bugüne
Alıntılar	2806	2111
h-endeksi	28	24
i10-endeksi	62	57

520

260

130

390

2010201120122013201420152016201720182019202020212022202320248 37 39 62 75 91 88 101 155 200 313 447 470 516 155

Genel erişim

Tümünü görüntüle

39 makale

2 makale

genel erişime açık olanlar

genel erişime açık olmayanlar

Finansman sağlayan kuruluşun getirdiği zorunluluğa dayalı olarak

Katkıda bulunan yazarlar

Vivek Subbiah, MDAssociate Professor, The University of Texas MD Anderson Cancer Centermdanderson.org üzerinde doğrulanmış e-posta adresine sahip
Alexander J. Lazar MD/PhDProfessor; Pathology, Genomic Medicine, Dermatology & Transl Molec Pathol, MD Anderson Cancer Ctrmdanderson.org üzerinde doğrulanmış e-posta adresine sahip
Funda Meric-BernstamChair, Department of Investigational Cancer Therapeutics, The UT MD Anderson Cancer Centermdanderson.org üzerinde doğrulanmış e-posta adresine sahip
Janos RoszikAssociate Professor, The University of Texas MD Anderson Cancer Centermdanderson.org üzerinde doğrulanmış e-posta adresine sahip
Behrang AminiThe University of Texas MD Anderson Cancer Centermdanderson.org üzerinde doğrulanmış e-posta adresine sahip
Roman GroisbergRutgers cancer institute of New JerseyRutgers.edu üzerinde doğrulanmış e-posta adresine sahip
Damon ReedSenior Member, Moffitt Cancer Centermoffitt.org üzerinde doğrulanmış e-posta adresine sahip
Jonathan ZagerDirector of Regional Therapies Moffitt Cancer Centermoffitt.org üzerinde doğrulanmış e-posta adresine sahip
Guillermo Garcia-ManeroMD Anderson Cancer Centermdanderson.org üzerinde doğrulanmış e-posta adresine sahip
Gang HanProfessor of Biostatistics, Texas A&M Universitytamu.edu üzerinde doğrulanmış e-posta adresine sahip
David ReynosoUTMButmb.edu üzerinde doğrulanmış e-posta adresine sahip
Hans GelderblomLUMClumc.nl üzerinde doğrulanmış e-posta adresine sahip
Oscar ArrietaHead of the Thoracic Oncology Unit, Instituto Nacional de Cancerología de Mexicounam.mx üzerinde doğrulanmış e-posta adresine sahip
Sebastian G. de la FuenteAdvent Health Orlando

Takip et

Anthony P Conley, MD

Associate Professor; Department of Sarcoma Medical Oncology; University of Texas MD Anderson Cancer

mdanderson.org üzerinde doğrulanmış e-posta adresine sahip

Rare cancers including chordomas chondrosarcomas rhabdomyosarcomas clear cell sarcomas malignant granular cell tumors


Başlık Alıntılara göre sırala Yıla göre sırala Başlığa göre sırala	Alıntı yapanlar Alıntı yapanlar	Yıl
Cause of death in patients with lower‐risk myelodysplastic syndrome F Dayyani, AP Conley, SS Strom, W Stevenson, JE Cortes, G Borthakur, ... Cancer 116 (9), 2174-2179, 2010	191	2010
Immuno-genomic landscape of osteosarcoma CC Wu, HC Beird, J Andrew Livingston, S Advani, A Mitra, S Cao, ... Nature communications 11 (1), 1008, 2020	166	2020
Epidemiology and therapies for metastatic sarcoma EK Amankwah, AP Conley, DR Reed Clinical epidemiology, 147-162, 2013	166	2013
Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials R Groisberg, DS Hong, A Behrang, K Hess, F Janku, S Piha-Paul, ... Journal for immunotherapy of cancer 5, 1-8, 2017	139	2017
The role of chemotherapy in advanced solitary fibrous tumors: a retrospective analysis MS Park, V Ravi, A Conley, SR Patel, JC Trent, DC Lev, AJ Lazar, ... Clinical sarcoma research 3, 1-7, 2013	113	2013
Clinical characteristics and outcomes for solitary fibrous tumor (SFT): a single center experience N DeVito, E Henderson, G Han, D Reed, MM Bui, R Lavey, L Robinson, ... PLoS One 10 (10), e0140362, 2015	103	2015
Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor WL Wang, A Conley, D Reynoso, L Nolden, AJ Lazar, S George, JC Trent Cancer chemotherapy and pharmacology 67, 15-24, 2011	95	2011
Uterine adenosarcoma: a review MJ Nathenson, V Ravi, N Fleming, WL Wang, A Conley Current oncology reports 18, 1-17, 2016	79	2016
Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes J Roszik, WL Wang, JA Livingston, CL Roland, V Ravi, C Yee, P Hwu, ... Clinical Sarcoma Research 7, 1-7, 2017	75	2017
Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas R Groisberg, DS Hong, V Holla, F Janku, S Piha-Paul, V Ravi, R Benjamin, ... Oncotarget 8 (24), 39254, 2017	73	2017
Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard JA Livingston, D Bugano, A Barbo, H Lin, JE Madewell, WL Wang, ... Scientific reports 7 (1), 11836, 2017	69	2017
Casting a wider net: Immunosurveillance by nonclassical MHC molecules MP D’Souza, E Adams, JD Altman, ME Birnbaum, C Boggiano, G Casorati, ... PLoS pathogens 15 (2), e1007567, 2019	59	2019
Immunotherapy: a new (and old) approach to treatment of soft tissue and bone sarcomas MJ Nathenson, AP Conley, E Sausville The oncologist 23 (1), 71-83, 2018	57	2018
Comprehensive characterization of malignant phyllodes tumor by whole genomic and proteomic analysis: biological implications for targeted therapy opportunities DLF Jardim, A Conley, V Subbiah Orphanet journal of rare diseases 8, 1-8, 2013	57	2013
Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial N Somaiah, AP Conley, ER Parra, H Lin, B Amini, LS Soto, R Salazar, ... The Lancet Oncology 23 (9), 1156-1166, 2022	56	2022
Progressive and reversible conduction disease with checkpoint inhibitors N Reddy, R Moudgil, JC Lopez-Mattei, K Karimzad, EN Mouhayar, ... Canadian Journal of Cardiology 33 (10), 1335. e13-1335. e15, 2017	53	2017
Phase II study of atezolizumab in advanced alveolar soft part sarcoma (ASPS) AR Naqash, GH O’Sullivan Coyne, N Moore, E Sharon, N Takebe, ... J Clin Oncol 39 (15_suppl), 11519, 2021	46	2021
Positive tumor response to combined checkpoint inhibitors in a patient with refractory alveolar soft part sarcoma: a case report AP Conley, CM Zobniw, K Posey, JD Martinez, OG Arrieta, WL Wang, ... Journal of global oncology 4, 2018	44	2018
Outcome of first‐line systemic treatment for unresectable conventional, dedifferentiated, mesenchymal, and clear cell chondrosarcoma A van Maldegem, AP Conley, P Rutkowski, SR Patel, I Lugowska, ... The Oncologist 24 (1), 110-116, 2019	43	2019
Synergistic induction of apoptosis by the Bcl-2 inhibitor ABT-737 and imatinib mesylate in gastrointestinal stromal tumor cells D Reynoso, LK Nolden, D Yang, SN Dumont, AP Conley, AGP Dumont, ... Molecular oncology 5 (1), 93-104, 2011	43	2011

Sistem, işlemi şu anda gerçekleştiremiyor. Daha sonra yeniden deneyin.

Makaleler 1–20

Yıllık alıntı sayısı

Mükerrer alıntılar

Birleştirilmiş alıntılar

Katkıda bulunan yazar ekleKatkıda bulunan yazarlar

Takip et

Alıntı yapanlar

Katkıda bulunan yazarlar